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Glycans are central to many biological processes, but efforts to define their functions at the 
molecular level have been frustrated by a lack of suitable technologies. Here we highlight 
chemical tools that are beginning to address this need.Like proteins and nucleic acids, glycans are vital biopol-
ymers found in organisms across all domains of life. In 
eukaryotes, glycans decorate cell-surface proteins and 
secreted proteins, where they are poised to mediate 
molecular recognition events (Varki et al., 1999). Glycans 
serve as points of attachment for viruses, bacteria, and 
other cells and participate in many facets of the vertebrate 
immune system. Inside the cell, they can direct protein 
trafficking and serve as regulatory switches for protein 
function. Specific changes in glycan profiles correlate with 
certain disease states such as cancer and inflammation, 
suggesting that glycans could be used in clinical diagnos-
tics and perhaps as targets for developing therapeutics.
These observations should stimulate an explosion 
of interest in glycobiology. But many researchers still 
express frustration when glycans are implicated at the 
nexus of their system of study. One fundamental problem 
is that glycans have complex, branched structures and 
are intrinsically heterogeneous. Thus, the vast majority 
of glycoproteins, which are estimated to comprise 50% 
of eukaryotic proteomes, have not been well-character-
ized at a molecular level. In cases where the structural 
details of protein-associated glycans are defined, their 
functions are still mostly unknown. Our current view of 
glycobiology therefore remains largely descriptive and 
focused at the cellular, rather than the molecular, level.
In other areas of biology, the gap between descriptive 
analysis and mechanistic inquiry has been bridged by 
experimental tools for perturbing, visualizing, and profil-
ing biopolymers. For example, molecular biology tech-
niques, such as gene disruption, overexpression, and 
silencing, allow the perturbation of specific proteins and 
their subsequent functional assignment. Fluorescent 
proteins such as GFP can serve as genetically encoded 
tags for protein visualization. GFP fusion proteins have 
been used in numerous studies of protein localization, 
dynamics, and association in both cells and living organ-
isms. Finally, DNA microarray technologies have driven 
the field of genomics, enabling the system-wide profiling 
of transcripts associated with physiological states.
Unfortunately, these powerful technologies cannot be 
directly extended to the study of glycans. Glycans are 
not primary gene products, making their genetic manip-
ulation far more complicated than for proteins or nucleic acids. Disruption of genes encoding glycan biosynthetic 
enzymes can effect changes in glycan structure and, in 
some studies, the phenotypes of these mutants have been 
instructive. But often, redundancies among related glyco-
syltransferases or embryonic lethality render mutant phe-
notypes impossible to interpret (Lowe and Marth, 2003). 
Furthermore, glycans are not amenable to being genetically 
tagged for visualization in living systems, nor can they be 
amplified for profiling. Lectins (receptor proteins that bind 
to glycans) and antibodies can be used to probe glycosyla-
tion at a global level, but these reagents cannot reveal the 
intricacies of glycan structures, their points of attachment 
to proteins, or more subtle alterations in glycan profiles 
that accompany physiological changes. Mechanistic stud-
ies of glycan function will benefit tremendously from tools 
for perturbing, visualizing, and profiling glycans in a more 
refined manner. Chemical tools have much to contribute in 
this regard and are the subject of this Minireview.
Perturbing Glycan Structures with Small Molecules
Small molecule inhibitors enable temporally controlled 
perturbation of a system in a reversible and tunable man-
ner. For studies of glycans, the most obvious targets for 
small molecule inhibition are glycosyltransferases, the 
enzymes that assemble glycans in the secretory pathway 
using nucleotide-sugar building blocks (Varki et al., 1999). 
Glycosyltransferase inhibitors have been identified from 
the pharmacopeia of natural products, most notably the 
Streptomyces metabolite tunicamycin. This uridine analog 
blocks the biosynthesis of N-linked glycans by disrupting 
the assembly of their common pentasaccharide core (Fig-
ure 1A). Tunicamycin has revealed numerous aspects of 
N-glycan function, including pivotal roles in protein folding 
and trafficking. However, global disruption of N-glycosyla-
tion causes a variety of effects that typically masks the 
function of a specific glycoprotein or glycan.
Recently, global inhibitors of mucin-type glycosylation, 
the most common form of O-linked glycosylation, have 
been developed via substrate-based design. Mucin-
type O-linked glycosylation (Figure 1B) is initiated by the 
polypeptide N-acetylgalactosaminyltransferases (ppGal-
NAcTs), a family of enzymes (?24 isoforms in humans) 
that use UDP-GalNAc as a common substrate. A synthetic 
compound library of uridine derivatives was screened Cell 126, September 8, 2006 ©2006 Elsevier Inc. 851
Figure 1. Common Cell Surface Glycans
(A) An N-linked glycan. The Man3GlcNAc2 pen-
tasaccharide core (blue) is conserved across 
all N-glycan structures and can be elaborated 
with N-acetyllactosamine units (green), sialic 
acid residues (brown), and other epitopes. 
(B) A mucin-type O-linked glycan. The core 
GalNAc moiety (blue), installed on a serine/
threonine residue by a member of the ppGal-
NAcT family, is common to all mucin-type O-
linked glycans. against members of the ppGalNAcT family, revealing 
two structurally related compounds that disrupt mucin-
type O-linked glycosylation in cultured cells and organs 
(Hang et al., 2004). Like tunicamycin, these compounds 
suppress O-linked glycosylation across the proteome, 
without specificity for discrete glycoprotein targets. This 
broad-spectrum inhibitory activity may account for the 
apoptotic effects observed when certain cell types are 
exposed to these reagents.
Small molecules that disrupt peripheral glycan “epitopes” 
are more likely to provide functional data without causing 
global cellular effects. This goal has been achieved using 
chemical “primers” of glycosylation (Brown et al., 2003). 
These cell-permeable small molecules—typically com-
prising hydrophobic glycosides of simple sugars—act as 
decoys for glycosyltransferases and thus compete with 
endogenous substrates for their activity. When supplied to 
cells, the primers suppress the elaboration of endogenous 
glycans, thereby perturbing the structures observed on 
cell-surface glycoproteins (Figure 2A). Concomitantly, 
the elaborated glycans can be observed on the primers, 
which are eventually secreted from the cell.
Among the most popular of these reagents is α-ben-
zyl GalNAc, a primer that competes for elaboration of the 
core GalNAc residue found in mucin-type O-linked glycans 
(Figure 2A). Studies using α-benzyl GalNAc to truncate O-
linked glycans suggest a link between this form of glyco-
sylation and cancer metastasis. Primers have also been 
used to perturb glycosaminoglycans (e.g., heparan sul-
fates) and complex cancer-associated glycans.
In addition to glycosyltransferases, other glycan-
processing enzymes can be targeted for inhibition with 
small molecules. Glycosidases, enzymes that remove 
sugars from glycans, are one example. Members of this 
enzyme family degrade glycans within lysosomes and 
processing N-linked glycans in the endoplasmic retic-
ulum and Golgi (Varki et al., 1999). The natural prod-
ucts deoxynojirimycin and swainsonine inhibit glycosi-
dases involved in N-linked glycan maturation and can 
be used to disrupt the elaboration of terminal epitopes 
on N-linked glycans. In the presence of these inhibi-
tors, N-linked glycans are installed on proteins, but their 
peripheral epitopes lack structures typically involved 
in molecular recognition. Thus, deoxynojirimycin and 
swainsonine can perturb N-linked glycan structures in a 
more refined manner than tunicamycin.
The above small molecule tools target the enzymes 852 Cell 126, September 8, 2006 ©2006 Elsevier Inc.involved in glycan assembly as either inhibitors or com-
petitive substrates. An alternative strategy for chemical 
perturbation involves the metabolic incorporation of chain 
terminators into the glycan. Similar to dideoxy nucleotides 
in a DNA polymerase reaction, deoxy or otherwise modi-
fied monosaccharides can be incorporated into glycans by 
the cell’s metabolic machinery, resulting in truncation of the 
glycan at that site (Figure 2B). For the strategy to succeed, 
the modified monosaccharide must be taken up by cells, 
processed into a nucleotide sugar substrate, and trans-
ferred by the relevant glycosyltransferases onto the appro-
priate glycan targets. Thus, substrate promiscuity among 
metabolic enzymes is a strict prerequisite. Hsieh-Wilson 
and coworkers recently treated neurons with 2-deoxyga-
lactose, which was integrated into glycans but refractory 
to further elaboration with fucose at the 2-position (Figure 
2B). The observed stunted neurite outgrowth and delayed 
synapse formation implicated the fucosylated glycans in 
proper neuronal development (Murrey et al., 2006).
Visualizing Glycans with Chemical Reporters
GFP and its relatives have revolutionized biology by enabling 
the visualization of proteins within authentic environments. 
Analogous tools for visualizing glycans could propel major 
advances in the field of glycobiology. At the cellular level, 
the ability to image glycans could enable studies of locali-
zation, trafficking, and dynamics. At the organismal level, 
glycan visualization would facilitate the real-time analysis 
of changes in glycosylation associated with development 
and disease. To date, these changes have been studied 
primarily by lectin and antibody staining of tissues ex vivo 
or inferred by expression profiling of glycosyltransferases. 
The direct monitoring of glycans within living animals using 
lectin or antibody conjugates is a promising direction, but 
these protein-based reagents have limited tissue access 
and may be restricted to imaging vascular targets.
An emerging approach toward glycan visualization 
exploits their underlying biosynthetic machinery for the 
incorporation of detectable probes. We have termed this 
the “bio-orthogonal chemical reporter” strategy (Figure 
2C) (Prescher and Bertozzi, 2005). First, a monosaccha-
ride substrate is modified with a functional group (the 
reporter) that is chemically inert in biological systems 
(hence the term “bio-orthogonal”). Upon administration 
to cells, the modified sugar is processed similarly to its 
native counterpart and integrated into cellular glycans. 
Finally, the labeled glycans are reacted with a detectable 
Figure 2. Strategies for Perturbing, 
 Visualizing, and Profiling Glycans
(A) Suppressing the elaboration of cell-surface gly-
cans with chemical primers. The primer α-benzyl 
GalNAc (blue) competes with endogenous sub-
strates for elaboration of the core GalNAc residue. 
Cells treated with this compound express truncat-
ed mucin-type O-linked glycans (monosaccharide 
units shown in black). 
(B) Blocking the extension of glycan chains with 
deoxy sugars. Neurons incubated with 2-deox-
yGal (blue) incorporate the sugar into cell-surface 
glycans but are unable to elaborate the epitope at 
the 2-position. The Fucα(1-2)Gal-deficient neurons 
display abnormal growth characteristics. 
(C) Visualizing and profiling glycans via the bio-or-
thogonal chemical reporter strategy. Synthetic azi-
dosugars are incorporated into cellular glycans by 
the cell’s metabolic machinery. In a second step, 
the azidosugars are detected. Depending on the 
choice of probe (e.g., fluorophore or affinity tag), 
this strategy can be used to image or enrich glyco-
conjugate subtypes. 
(D) Profiling glycans with lectin microarrays (Hsu et 
al., 2006). Chips arrayed with lectins are incubated 
with fluorescently labeled biomolecules, cells, or 
tissue lysates. The pattern of bound glycoconju-
gates provides a readout of specific classes of gly-
can structures that are present in the mixture.probe linked to a complementary bio-orthogonal func-
tional group. The mutually selective chemical reactivity of 
the two functional groups ensures that only the metaboli-
cally labeled glycans are targeted for detection.
This approach hinges on the selection of a reporter group 
that can be readily installed on monosaccharide substrates 
with minimal perturbation to their structures. This require-
ment precludes the use of conventional fluorophores or 
affinity reagents (e.g., biotin), which are large relative to the 
sugar and likely to impede enzymatic processing within 
cells. We have found that organic azides (R-N3) are ideal 
chemical reporters. Azides are small functional groups 
that are metabolically stable, essentially inert in biologi-
cal systems, and selectively reactive with phosphines via 
the Staudinger ligation or alkynes via a [3+2] cycloaddition 
(Figure 2C). We and others have visualized numerous gly-
can types on living cells using the bio-orthogonal chemi-
cal reporter strategy (Dube and Bertozzi, 2003; Keppler 
et al., 2001). For example, azido analogs of ManNAc (i.e., 
N-azidoacetylmannosamine, ManNAz) and GalNAc (i.e., 
N-azidoacetylgalactosamine, GalNAz) have been used 
to tag sialylated and mucin-type O-linked glycoproteins, 
respectively, with detectable probes. Importantly, both azi-
dosugar metabolism and subsequent chemical reactions 
are well tolerated by cultured cells.
Extension of the bio-orthogonal chemical reporter 
system to the visualization of glycans in living animals 
appears possible. In an important precedent, both the 
metabolic labeling of sialylated glycans with ManNAz 
and subsequent chemical reaction with a phosphine 
reagent were achieved in mice (Prescher and Bertozzi, 
2005). Similarly, mucin-type O-linked glycans were 
labeled with GalNAz and then reacted with a phosphine 
probe in vivo (Dube et al., 2006). This work is now being applied to the noninvasive imaging of glycans in living 
animals, with the goal of monitoring changes in glyco-
sylation associated with disease in real-time.
Profiling Glycans—The Emerging Field of Glycomics
System-wide analyses of transcripts and proteins, the 
heart of genomics and proteomics, have vastly increased 
our understanding of a cell’s biochemical pathways. The 
revelation that many cellular systems, such as primary 
metabolism and transcription, are intimately connected 
has generated renewed appreciation for biological com-
plexity at the systems level. The availability of complete 
genome sequences for many organisms provides a blue-
print from which to infer their chemical makeup. Already, 
great strides have been made in relating an organism’s 
genome to its proteome. A major frontier in systems biol-
ogy is to further relate the genome and proteome to an 
organism’s complete repertoire of glycans—the glycome 
(Murrell et al., 2004). Taking inventory of an organism’s 
glycome is the first step in this process.
Like the other “omics” efforts, glycomics is being driven 
by new technologies for high-throughput profiling, several 
of which are rooted in chemistry. Glycan profiling can be 
performed at various hierarchical levels of structural infor-
mation content. A first level of inquiry might be the identi-
fication of all glycoproteins bearing certain monosaccha-
ride components and fluctuations in sugar modifications 
that are associated with physiological changes. As an 
example, numerous cytosolic and nuclear proteins are 
modified in a dynamic fashion with the monosaccharide 
β-O-GlcNAc linked to serine or threonine residues. This 
form of glycosylation is thought to play a role in regulat-
ing protein function (similar to phosphorylation), but the 
complete inventory of proteins modified with β-O-GlcNAc Cell 126, September 8, 2006 ©2006 Elsevier Inc. 853
is unknown. A convenient approach to profiling these 
proteins involves the bio-orthogonal chemical reporter 
strategy mentioned above. Zhao and coworkers (Nandi 
et al., 2006) metabolically labeled cultured cells with N-
azidoacetylglucosamine (GlcNAz) and then tagged the 
labeled proteins with a phosphine-biotin conjugate. Sub-
sequent affinity capture and mass spectrometry analysis 
revealed many previously unidentified proteins bearing 
the β-O-GlcNAc modification. A similar approach can be 
applied to profiling sialylated or mucin-type O-linked glyc-
oproteins using the appropriate azidosugar substrates.
A second level of inquiry might involve the profiling 
of higher-order glycan structures comprising specific 
linkage patterns. Subtle changes in the connectivity 
of monosaccharide units can have profound biological 
consequences, many of which have been correlated 
with stages of development or pathogenesis. The ability 
to profile diverse glycan structures has been aided by a 
battery of commercial antibodies and naturally occurring 
lectins. These reagents can be immobilized on microar-
rays, which are then incubated with fluorescently labeled 
tissue or cell lysates. The pattern of bound glycocon-
jugates provides a profile of specific classes of glycan 
structures that are present in the sample (Figure 2D).
Lectin/antibody microarrays provide high-throughput 
analysis with moderate structural information content but are 
limited by the number of discrete glycan epitopes for which 
complementary lectins or antibodies are available. Thus, 
this profiling method will not detect all glycans in a complex 
sample, nor will it provide complete structural assignments 
for most glycans. To satisfy this level of inquiry, mass spec-
trometry has been artfully employed (Dell and Morris, 2001; 
Morelle and Michalski, 2005). This technique can provide 
detailed structural information on glycans, including com-
position, connectivity of monosaccharides, and the identity 
of underlying protein or lipid scaffolds. Furthermore, high-
resolution mass spectrometry techniques can simultane-
ously analyze many glycan structures from complex cell or 
tissue samples. Combined with chromatographic separa-
tions, mass spectrometry has the potential to fully define 
an organism’s glycome. However, considerable expertise in 
instrumentation and sample preparation is required for this 
level of glycan analysis (Park and Lebrilla, 2005).
In addition to glycan profiling, there is parallel inter-
est in characterizing the glycan binding activities of iso-
lated proteins and intact cells. Homogeneous samples 
of glycans are required for this purpose, underscoring 
the importance of advances in carbohydrate chemistry 
(Hanson et al., 2004). Already, synthetic glycans have 
been arrayed on chips and integrated into water-solu-
ble probes for high-throughput profiling of living cells 
(Kiessling et al., 2000; Paulson et al., 2006).
Future Outlook
The chemical tools highlighted above for perturbing, visu-
alizing, and profiling glycans have reduced the barriers to 
experimental pursuit that have historically plagued these 
biopolymers. Still, the experimental playing field is far from 854 Cell 126, September 8, 2006 ©2006 Elsevier Inc.level with that for proteins or nucleic acids, and expansion 
of the chemical toolkit should therefore be a continuous 
effort. Additionally, for the expanding chemical toolkit to 
impact the field of glycobiology, new technologies must 
be transferred from chemistry to biology laboratories and, 
when possible, used in combination with prevailing genetic 
and biochemical tools. Biological researchers need access 
to small molecule inhibitors, metabolic labels, and syn-
thetic glycans, as well as instrumentation and expertise 
for microarray and mass spectrometry profiling. Similar 
needs for genomic and proteomic technologies prompted 
the development of core facilities in academic centers and 
commercial services in the private sector. Likewise, we 
anticipate that biologists interested in studying glycans will 
benefit tremendously from recently formed core facilities 
that provide reagents, databases, and analytical services 
to the community at large (Raman et al., 2005).
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